The Day In Review: SciClone Pharmaceuticals, Inc. Soars On Positive Melanoma Results

December 22, 2006 -- SciClone Pharma reported Zadaxin increased median survival in melanoma patients; New River received a second Approvable letter for its lead ADHD drug; Valeant sold off its HIV and cancer development programs; Novartis received FDA approval of Exforge, a combination of two high blood pressure medications; Exelixis began a Phase II trial of XL880 for gastric cancer; Allergan received an Approvable letter for Combigan, a treatment for elevated intraocular pressure; and after the bell, Amylin and Lilly announced their insulin mimetic Byetta received an additional indication. The Centient Biotech 200™ lost 21 points to close at 3922, a drop of .54%. More details...

Back to news